Vertex Pharmaceuticals Incorporated (VRTX) |
|
347.74 -4.76 (-1.35%)
|
09-29 16:00 |
|
Open: |
351.94 |
Pre. Close: |
352.5 |
|
High:
|
354.18 |
Low:
|
347.26 |
|
Volume:
|
833,661 |
Market Cap:
|
89,750(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:31:10 PM |
|
Short-term rate:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 410.9 One year: 418.83 |
| Support: |
Support1: 340.82 Support2: 283.57 |
| Resistance: |
Resistance1: 351.8 Resistance2: 358.58 |
| Pivot: |
350.5  |
| Moving Average: |
MA(5): 350.45 MA(20): 349.41
MA(100): 346.21 MA(250): 322.87 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.6 |
| Stochastic oscillator: |
%K(14,3): 46.4 %D(3): 52.4 |
| RSI: |
RSI(14): 47 |
| 52-week: |
High: 367 Low: 282.2 |
| Average Vol(K): |
3-Month: 973 (K) 10-Days: 760 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRTX ] has closed above bottom band by 27.2%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
354.7 - 356.49 |
356.49 - 357.96 |
|
Low:
|
343.13 - 345.02 |
345.02 - 346.58 |
|
Close:
|
344.98 - 347.93 |
347.93 - 350.36 |
|
Company Description |
|
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. |
Headline News |
Sun, 01 Oct 2023
2 Brilliant Growth Stocks to Invest $2000 in Right Now - Nasdaq
Sun, 01 Oct 2023
Birch Hill Investment Advisors LLC Decreases Position in Vertex ... - MarketBeat
Fri, 29 Sep 2023
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Sector ... - Nasdaq
Fri, 29 Sep 2023
Sumitomo Life Insurance Co. Acquires 2814 Shares of Vertex ... - MarketBeat
Wed, 27 Sep 2023
Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock on Wednesday? - InvestorsObserver
Fri, 22 Sep 2023
Is Vertex Pharmaceuticals Incorporated (VRTX) Stock Over or Undervalued? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
258 (M) |
| Shares Float |
257 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
96.5 (%) |
|
Shares Short
|
2,920 (K) |
|
Shares Short P.Month
|
2,860 (K) |
Stock Financials |
|
EPS
|
13 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
60 |
|
Profit Margin (%)
|
35.4 |
|
Operating Margin (%)
|
47 |
|
Return on Assets (ttm)
|
15.5 |
|
Return on Equity (ttm)
|
24.5 |
|
Qtrly Rev. Growth
|
13.5 |
|
Gross Profit (p.s.)
|
20.61 |
|
Sales Per Share
|
36.84 |
|
EBITDA (p.s.)
|
17.93 |
|
Qtrly Earnings Growth
|
12.5 |
|
Operating Cash Flow
|
4,070 (M) |
|
Levered Free Cash Flow
|
3,630 (M) |
Stock Valuations |
|
PE Ratio
|
26.74 |
|
PEG Ratio
|
2.3 |
|
Price to Book value
|
5.79 |
|
Price to Sales
|
9.43 |
|
Price to Cash Flow
|
22.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
